RxDoctor Payments Data

Jude Ezechukwu, MD

Internal Medicine · Erie, PANPI 1154809200

Payments from drug & device makers

$2,868in general payments, 2019–2025

Across 128 payments — averaging $22.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$565
  • Johnson & Johnson$469
  • Gilead$261
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$242
  • E.r. Squibb & Sons, L.L.C.$229
  • Pfizer$205
  • plus $897 from 12 others

What the payments were for

  • Food & beverage$2,868100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,868 in reported general payments places this provider in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$67,615
Medicare patients
196
Services billed
717

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban90$56,978
EntrestoSacubitril/Valsartan45$29,873
JardianceEmpagliflozin55$29,319
FarxigaDapagliflozin Propanediol19$10,750
Bumetanide85$1,436
Metoprolol Succinate154$673
Amlodipine Besylate127$391
Atorvastatin Calcium42$313
Lisinopril21$239
Potassium Chloride23$227
Carvedilol50$193
Hydralazine Hcl30$191
Losartan Potassium24$190
Levetiracetam23$172
Tamsulosin Hcl30$141

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$205$56,97890 claims
NovartisEntresto$565$29,87345 claims
Boehringer IngelheimJardiance$43$29,31955 claims
AstraZenecaFarxiga$182$10,75019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Erie

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →